COVID-19 Vaccine Gives Moderna $18bn Launchpad Into HIV Vaccine, Cancer Therapies
CMO Tal Zaks To Depart
A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.
You may also be interested in...
An EUA would carve out a market advantage, although Moderna should be releasing similar data soon for its COVID-19 vaccine.
In this week's podcast edition of Scrip's Five Must-Know Things, hear about Sanofi’s rebates, Moderna’s business prospects, US views on coronavirus vaccine comparisons, Piot talk about virus variants, and new results for Amgen's asthma drug.
The firms' messenger RNA alliance inked back on 2013 is still very much ongoing but AstraZeneca decided to sell its considerable stake in the high-profile biotech to help finance its own pipeline.